Meeting
2019 ASCO Annual Meeting
A multi-center phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresectable biliary tract cancer.
Authors
Vaibhav Sahai
University of Michigan, Ann Arbor, MI
Vaibhav Sahai , Tyler Howard Buckley , Kent A. Griffith , Mark Zalupski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03785873
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS4154)
DOI
10.1200/JCO.2019.37.15_suppl.TPS4154
Abstract #
TPS4154
Poster Bd #
252b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multicenter phase Ib/II study of liposomal-irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) with nivolumab as second-line therapy for patients with advanced biliary tract cancer (BilT-03).
First Author: Vaibhav Sahai
Poster
2019 ASCO Annual Meeting
A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).
First Author: Richard D. Kim
Poster
2024 ASCO Annual Meeting
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.
First Author: Jieer Ying
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben